Core Insights - Omada Health's 12-month analysis of its GLP-1 companion program shows significant weight loss among participants, with an average of 18.4% weight loss for those who persisted on medication, compared to 11.9% in real-world evidence [1][2] - The program demonstrated that members achieved 47% greater weight loss on semaglutide and 37% greater weight loss on tirzepatide compared to published real-world evidence [1][2] - Overall, participants in the program experienced an average weight loss of 16.3%, nearly double that observed in real-world analyses [1][2] Program Effectiveness - 67% of Omada members remained on their GLP-1 medications for one year, surpassing the 47-49% persistence rate found in comparable studies [2] - Members who discontinued medication before one year achieved a 13.1% average weight loss, compared to 6.8% among similar patients in other studies [2] Support and Care Model - Omada's Enhanced GLP-1 Care Track provides comprehensive support, helping members navigate their weight loss journey and manage medication side effects [3] - The program combines specialized GLP-1-focused care team support with tailored content, enhancing the medication experience for members [3] Real-World Data and Insights - Omada emphasizes the importance of real-world data, tracking outcomes in real-time to ensure the effectiveness of its programs as medications and access evolve [4] - The study is part of the Omada Insights Lab ANSWERS Initiative, which analyzes real-world data from behavior change weight health programs [4] Company Overview - Omada Health is a virtual healthcare provider focused on cardiometabolic conditions, including obesity, and supports members taking GLP-1s and other anti-obesity medications [5] - The company has served over one million members and has over 30 peer-reviewed publications demonstrating its clinical and economic results [6]